

Evgenii A Osmanov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3864231/publications.pdf>

Version: 2024-02-01

11
papers

685
citations

1478505

6
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

1121
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: basic characteristics, pathogenetic mechanisms, treatment strategies and problems of clinical practice. Russian Journal of Pediatric Hematology and Oncology, 2020, 7, 94-111.	0.3	2
2	Thrombotic microangiopathy associated with hematopoietic stem cell transplantation: general characteristics and an example from clinical practice. Russian Journal of Pediatric Hematology and Oncology, 2020, 7, 86-93.	0.3	1
3	Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. Leukemia and Lymphoma, 2019, 60, 172-179.	1.3	11
4	Complex cytogenetic research of cryptic chromosomal aberrations in patients with multiple myeloma. , 2019, 18, 50-59.	0.3	1
5	Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncology, The, 2018, 19, 1449-1458.	10.7	93
6	EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE. Uspehi Molekularnoj Onkologii, 2018, 5, 62-70.	0.3	2
7	Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood, 2015, 126, 1893-1901.	1.4	117
8	Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. New England Journal of Medicine, 2015, 372, 944-953.	27.0	343
9	Tumor-associated cytotoxic lymphocytes and macrophages as predictive factors in follicular lymphoma. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2014, 8, 198-205.	0.6	1
10	Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib-Rituximab Versus Rituximab. Clinical Cancer Research, 2013, 19, 2551-2561.	7.0	16
11	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncology, The, 2011, 12, 773-784.	10.7	98